StockData
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. (FDMT) stock

FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3015% below fair value
$10.79−0.50 (-4.43%)

Close on Nov 17, 2026Market cap $778.82MP/E –Yield –

4D Molecular Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

4D Molecular Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$197.12M. For fiscal 2025 it was -$159.55M. The highest annual figure on record is -$50.76M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$159.55M–
FY2024Dec 31, 2024-$187.84M–
FY2023Dec 31, 2023-$112.87M–
FY2022Dec 31, 2022-$110.03M–
FY2021Dec 31, 2021-$71.33M–
FY2020Dec 31, 2020-$56.66M–
FY2019Dec 31, 2019-$50.76M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$77.03M–
Q1 FY2026Mar 31, 2026-$73.62M–
Q4 FY2025Dec 31, 2025$14.72M–
Q3 FY2025Sep 30, 2025-$61.19M–
Q2 FY2025Jun 30, 2025-$59.46M–
Q1 FY2025Mar 31, 2025-$53.62M–
Q4 FY2024Dec 31, 2024-$56.12M–
Q3 FY2024Sep 30, 2024-$51.13M–
Q2 FY2024Jun 30, 2024-$42.46M–
Q1 FY2024Mar 31, 2024-$38.14M–
Q4 FY2023Dec 31, 2023-$36.65M–
Q3 FY2023Sep 30, 2023-$13.97M–
Q2 FY2023Jun 30, 2023-$32.14M–
Q1 FY2023Mar 31, 2023-$30.11M–
Q4 FY2022Dec 31, 2022-$28.72M–
Q3 FY2022Sep 30, 2022-$26.50M–
Q2 FY2022Jun 30, 2022-$28.43M–
Q1 FY2022Mar 31, 2022-$26.39M–
Q4 FY2021Dec 31, 2021-$24.76M–
Q3 FY2021Sep 30, 2021-$22.66M–
Q2 FY2021Jun 30, 2021-$7.60M–
Q1 FY2021Mar 31, 2021-$16.31M–
Q4 FY2020Dec 31, 2020-$20.42M–
Q3 FY2020Sep 30, 2020-$7.82M–
Q2 FY2020Jun 30, 2020-$15.15M–
Q1 FY2020Mar 31, 2020-$13.28M–

More 4D Molecular Therapeutics figures

See a number that looks wrong?